CAM
CATX icon

ClariVest Asset Management’s Perspective Therapeutics CATX Stock Holding History

ClariVest Asset Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$540K Hold
54,199
– – 0.06% 344
2024
Q2 		$540K Buy
+54,199
New +$784K 0.06% 344

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ClariVest Asset Management's CATX Position: Q3 2024 in Review

ClariVest Asset Management held its Perspective Therapeutics (CATX) position steady in Q3 2024 at 54,199 shares worth $540K. The position accounts for 0.06% of the portfolio, ranked #344.

ClariVest Asset Management first reported a position in CATX in Q2 2024 and has held it in 2 quarters since. 127 funds tracked by Wall St. Rank hold CATX as of Q3 2024.

  • ClariVest Asset Management held 54,199 shares of Perspective Therapeutics worth $540K as of Q3 2024.
  • ClariVest Asset Management left its Perspective Therapeutics share count unchanged in Q3 2024.
  • Perspective Therapeutics made up 0.06% of ClariVest Asset Management's portfolio in Q3 2024, its #344 holding.
  • ClariVest Asset Management first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 127 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.